I compiled a summary of US sales for DAYBUE and SKYCLARYS, same launch time, DAYBUE has been performing better than SKYCLARYS in sales in US.
Given SKYCLARYS/Reata was acquired in 2023 for US$7.3B, NEU is still valued at US$1.05B with net cash around $320m including US$50m milestone payment to receive this quarter less accrued income tax.
According to Acadia sale guidance, NEU will receive royalties for 2025 DAYBUE sales, royalties will be around $64m to $69m, then likely another milestone payment for first Europe sale of US$35m/$55m, and bank interest income around $16m, NEU 2025 income are likely to be around $135m to $140m, on top of existing net cash position of around $320m, based on my estimates.
DYOR & ALL IMO.
![]()
- Forums
- ASX - By Stock
- NEU
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.06%
!
$17.89

Acadia, page-1357
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$17.89 |
Change
0.010(0.06%) |
Mkt cap ! $2.252B |
Open | High | Low | Value | Volume |
$17.93 | $17.97 | $17.64 | $2.423M | 135.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 321 | $17.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.90 | 889 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 316 | 17.910 |
3 | 284 | 17.900 |
5 | 389 | 17.890 |
7 | 494 | 17.880 |
6 | 975 | 17.870 |
Price($) | Vol. | No. |
---|---|---|
17.930 | 180 | 4 |
17.940 | 327 | 5 |
17.950 | 271 | 3 |
17.960 | 384 | 3 |
17.970 | 8382 | 6 |
Last trade - 10.39am 13/08/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |